Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma

Arabinda Das, Fraser Henderson, Stephen Lowe, Gerald C. Wallace, William A. Vandergrift, Scott M. Lindhorst, Abhay K. Varma, Libby K. Infinger, Pierre Giglio, Narendra L. Banik, Sunil J. Patel, David Cachia

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Purpose/introduction: Glioblastoma (GB) remains incurable despite aggressive chemotherapy, radiotherapy, and surgical interventions; immunotherapies remain experimental in clinical practice. Relevant preclinical models that can accurately predict tumor response to therapy are equally challenging. This study aimed to validate the effect of the naturally occurring agent diallyl trisulfide (DATS) in human GB in relevant pre-clinical models. Methods: Ex vivo slice culture, in vivo cell line derived orthotopic xenograft and patient-derived orthotopic xenograft (PDX) animal models of GB were utilized to assess efficacy of treatment with DATS. Results: Our results showed 72-h treatments of 25 µM DATS induced cell death in ex vivo human GB slice culture. We treated U87MG orthotopic xenograft models (U87MGOX) and patient-derived orthotopic xenograft models (PDX) with daily intraperitoneal injections of DATS for 14 days. Magnetic resonance (MR) imaging of mice treated with DATS (10 mg/kg) demonstrated reduced tumor size at 5 weeks when compared with saline-treated U87MGOX and PDX controls. Hematoxylin (H&E) staining demonstrated dose-dependent reduction in gross tumor volume with decreased proliferation and decreased angiogenesis. Western blotting showed that DATS was associated with increases in histone acetylation (Ac-Histone H3/H4) and activated caspase-3 in this novel preclinical model. Histological assessment and enzyme assays showed that even the highest dose of DATS did not negatively impact hepatic function. Conclusions: DATS may be an effective and well-tolerated therapeutic agent in preventing tumor progression and inducing apoptosis in human GB.

Original languageEnglish (US)
Pages (from-to)945-952
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Issue number6
StatePublished - Dec 1 2018
Externally publishedYes


  • DATS
  • Diallyl trisulfide
  • GB
  • Glioblastoma
  • Histone deacetylase inhibitor
  • PDX: patient-derived orthotopic xenograft

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)


Dive into the research topics of 'Single agent efficacy of the HDAC inhibitor DATS in preclinical models of glioblastoma'. Together they form a unique fingerprint.

Cite this